Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761671 | 1.00 | ABCG2 (0.44) | ABCG2EDNRAABCB1PDE5AMAOB | |
| SCHEMBL2761692 | 0.92 | ABCG2 (0.43) | ABCG2EDNRAABCB1PDE5AMAOB | |
| SCHEMBL2761691 | 0.92 | ABCG2 (0.43) | ABCG2EDNRAABCB1PDE5AMAOB | |
| SCHEMBL2761687 | 0.84 | EDNRA (0.45) | ABCG2EDNRAABCB1PDE5AMAOB | |
| SCHEMBL2761558 | 0.83 | EDNRA (0.46) | ABCG2EDNRAABCB1MAOBMAOA | |
| SCHEMBL4203732 | 0.82 | EDNRA (0.45) | ABCG2EDNRAABCB1MAOBMAOA | |
| SCHEMBL2761742 | 0.78 | LMNA (0.41) | ACHEALDH1A1 | |
| SCHEMBL2761741 | 0.78 | LMNA (0.41) | ACHEALDH1A1 | |
| SCHEMBL2761617 | 0.76 | EDNRA (0.54) | ABCG2EDNRAABCB1MAOBMAOA | |
| SCHEMBL2761975 | 0.76 | PDE4A (0.38) | MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | ABCG2 722/4885EDNRA 598/4885ABCB1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.